Associated Papers
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Tsao AS et al.
Jco Precision Oncology, 2025
Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N et al.
Proteins, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-no-BCR-ABL1
SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas.
Kim AL et al.
The Journal of Investigative Dermatology, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
30053901 (PubMed )
Supplement: 13073_2018_564_MOESM2_ESM.xlsx › 3
A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A et al.
Bmc Cancer, 2018
AKT1 Activation is Obligatory for Spontaneous BCC Tumor Growth in a Murine Model that Mimics Some Features of Basal Cell Nevus Syndrome.
Kim AL et al.
Cancer Prevention Research (philadelphia, Pa.), 2016
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S et al.
Molecular Oncology, 2015
Select a paper to view details